Lung cancer trials in Germany

In Germany 182 Also abroad 2733

182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Bad Berka, Berlin, Dresden, Gauting, Giessen, Hamburg, Heidelberg, Kassel, Mannheim
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
Phase 3Taking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Berlin, Dortmund, Essen, Gera, Luebeck, Solingen
Age
18 years and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Bad Berka, Berlin, Bielefeld, Bochum, Cologne, Esslingen am Neckar, Frankfurt am Main, Gauting, Giessen, Grosshansdorf, Hamburg, Hanover, Heidelberg, Hemer, Homburg, Jena, Kassel, Kiel, Krefeld, Magdeburg, Minden, Moers, Munich, Oldenburg in Holstein, Regensburg, Schwerin, Wuerzburg
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Frankfurt am Main, Giessen
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 1Taking people
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Where
Augsburg, Cologne, Dresden, Giessen, Oldenburg
Age
18 years and over
People
554 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00
Phase 3Taking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Berlin, Bonn, Cologne, Essen, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Kempten (Allgau), Kiel, Koblenz, Munich, Nuremberg, Potsdam, Ravensburg
Age
18 years and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Bad Berka, Bielefeld, Bochum, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt am Main, Gauting, Giessen, Grosshansdorf, Halle, Hamburg, Hanover, Hemer, Homburg, Karlsruhe, Kassel, Kiel, Krefeld, Magdeburg, Minden, Moers, Munich, Oldenburg in Holstein, Regensburg, Schwerin, Velbert, Wuerzburg
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
Phase 3Taking people
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Where
Berlin, Essen, Munich, Oldenburg
Age
18 years and over
People
390 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717 · EU 2024-519901-36-00
Phase 1/2Taking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Munich, Regensburg, Wuerzburg
Age
18 years and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
Phase 1/2Taking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
Augsburg, Cologne, Frankfurt Am Main, Freiburg im Breisgau, Hemer, Jena, Loewenstein, Oldenburg in Holstein, Wuerzburg
Age
18 years and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Berlin, Cologne, Esslingen am Neckar, Flensburg, Frankfurt am Main, Gera, Giessen, Halle (Saale), Hannover, Hemer, Herne, Jena, Munich, Oldenburg, Stuttgart, Ulm, Wuerzburg
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 2Taking people
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Where
Berlin, Giessen, Immenhausen
Age
18 years and over
People
180 worldwide
Run by
AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00
Phase 1/2Not yet taking people in Germany
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Mainz, Stuttgart
Age
18 years and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Frankfurt
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 2Taking people
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Where
Bielefeld, Essen, Esslingen am Neckar, Gauting, Grosshansdorf, Heidelberg, Moers, Wuerzburg
Age
18 years and over
People
131 worldwide
Run by
CatalYm GmbH
See details and how to joinNCT07246863 · EU 2024-516794-70-00
Phase 3Not yet taking people in Germany
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden
Where
Berlin, Bremen, Dortmund, Dresden, Esslingen am Neckar, Frankfurt Am Main, Hemer, Homburg, Landshut, Munich, Regensburg, Saarbrücken, Wermelskirchen, Westerstede, Witten, Wuppertal
Age
18 years and over
People
230
Run by
AIO-Studien-gGmbH
See details and how to joinNCT07715396 · EU 2026-525497-18-00
Phase 2Taking people
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
Where
Berlin, Bielefeld, Cologne, Dresden, Essen, Flensburg, Frankfurt Am Main, Goettingen, Hemer, Mainz, Minden, Moers, Munich, Stuttgart
Age
18 years and over
People
57
Run by
AIO-Studien-gGmbH
See details and how to joinNCT07803848 · EU 2025-522437-65-00
Phase 3Taking people
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
Where
Aachen, Berlin, Bonn, Essen, Gauting, Giessen, Grosshansdorf, Halle (saale), Heidelberg, Kassel, Munich, Stuttgart
Age
18 years and over
People
340 worldwide
Run by
OSE Immunotherapeutics
See details and how to join2023-509340-10-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Essen, Esslingen am Neckar, Giessen, Leipzig, Mainz, Mannheim
Age
18 years and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
Phase 2/3Taking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Bonn, Donauwoerth, Essen, Goeppingen, Grosshansdorf, Hemer, Immenhausen, Loewenstein, Munich, Oldenburg, Regensburg, Stuttgart, Traunstein, Tuebingen, Ulm
Age
18 years and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
Phase 3Taking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Berlin, Brunswick, Cologne, Dortmund, Erfurt, Essen, Gera, Kaiserslautern, Landshut, Langen (Hessen), Luebeck, Rosenheim, Solingen, Wangen Im Allgaeu, Wiesbaden
Age
18 years and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
Phase 2Taking people
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Cologne, Frankfurt Am Main, Halle (saale), Homburg, Marburg, Stuttgart
Age
18 years and over
People
160 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00
Phase 1/2Taking people
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Where
Berlin, Dresden, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Heidelberg
Age
18 years and over
People
880 worldwide
Run by
BioNTech SE
See details and how to joinNCT07111520 · EU 2024-519344-32-00
Phase 1Not yet taking people in Germany
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Cologne, Essen
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Berlin, Bochum, Chemnitz, Esslingen am Neckar, Hamburg, Löwenstein, Minden, Munich
Age
18 years and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834